129 related articles for article (PubMed ID: 18219181)
1. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
3. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
4. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
6. Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis.
Majima T; Shimatsu A; Satoh N; Komatsu Y; Fukao A; Ninomiya K; Matsumura T; Nakao K
J Bone Miner Metab; 2008; 26(2):178-84. PubMed ID: 18301975
[TBL] [Abstract][Full Text] [Related]
7. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
8. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Sanad Z; Ellakwa H; Desouky B
Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
Luckey M; Kagan R; Greenspan S; Bone H; Kiel RD; Simon J; Sackarowitz J; Palmisano J; Chen E; Petruschke RA; de Papp AE
Menopause; 2004; 11(4):405-15. PubMed ID: 15243278
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis.
Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
Endocr J; 2007 Dec; 54(6):855-62. PubMed ID: 17917307
[TBL] [Abstract][Full Text] [Related]
11. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
12. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF
Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
[TBL] [Abstract][Full Text] [Related]
13. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
14. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
[TBL] [Abstract][Full Text] [Related]
15. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
16. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
[TBL] [Abstract][Full Text] [Related]
17. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
18. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
Gorai I; Hattori S; Tanaka Y; Iwaoki Y
J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
[TBL] [Abstract][Full Text] [Related]
19. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
